PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT05313165

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
LimFlow, Inc. (from the registry)
Registry
  • NCT NCT05313165
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT05313165. Allocation not applicable; no masking; primary purpose treatment. Start 2022-12-22 (actual); primary completion 2027-05-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
PROMISE III: Percutaneous Deep Vein Arterialization for the Treatment of Late-Stage Chronic Limb-Threatening Ischemia
Condition
Critical Limb Ischemia
Condition
Chronic Limb-Threatening Ischemia
Condition
Peripheral Arterial Disease
Intervention (Device)
LimFlow Stent Graft System
Lead sponsor
LimFlow, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05313165
Content hash
1c51a3a81824e99df8f4d83d2d88d9f9b3fe5c3ab7324fed0b5b8b05f543c842